Home » Stocks » United Therapeutics

United Therapeutics Corporation (UTHR)

Stock Price: $112.20 USD -0.87 (-0.77%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 4.98B
Revenue (ttm) 1.43B
Net Income (ttm) 429.80M
Shares Out 44.41M
EPS (ttm) 9.76
PE Ratio 11.50
Forward PE 9.84
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 6, 2020
Last Price $112.20
Previous Close $113.07
Change ($) -0.87
Change (%) -0.77%
Day's Open 113.30
Day's Range 111.69 - 113.55
Day's Volume 179,391
52-Week Range 75.58 - 127.79

More Stats

Market Cap 4.98B
Enterprise Value 4.22B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 44.41M
Float 40.03M
EPS (basic) 9.79
EPS (diluted) 9.76
FCF / Share 13.54
Dividend n/a
Dividend Yield n/a
Earnings Yield 8.70%
FCF Yield 11.98%
Payout Ratio n/a
Shares Short 2.33M
Short Ratio 3.45
Short % of Float 4.97%
Beta 0.86
PE Ratio 11.50
Forward PE 9.84
P/FCF Ratio 8.35
PS Ratio 3.48
PB Ratio 1.63
Revenue 1.43B
Operating Income 554.10M
Net Income 429.80M
Free Cash Flow 597.00M
Net Cash 760.70M
Net Cash / Share 17.13
Gross Margin 93.03%
Operating Margin 38.72%
Profit Margin 30.00%
FCF Margin 41.72%
ROA 8.55%
ROE 15.21%
ROIC 15.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 6
Overweight 0
Hold 3
Underweight 1
Sell 1

Analyst Consensus: Overweight

Price Target

$144.44*
(28.73% upside)
Low
95.0
Current: $112.20
High
244.0
Target: 144.44
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1,4491,6281,7251,5991,4661,2891,117916743593
Revenue Growth-11%-5.65%7.91%9.07%13.76%15.36%21.93%23.26%25.35%-
Gross Profit1,3311,4291,6201,5261,3971,163986797654525
Operating Income-1888058151,062699539292422318171
Net Income-105589418714652340175304218106
Shares Outstanding43.8043.5044.0043.8046.0048.2050.0852.0957.1656.14
Earnings Per Share-2.3913.399.3115.2512.726.283.285.713.671.78
EPS Growth-43.82%-38.95%19.89%102.55%91.46%-42.56%55.59%106.18%-
Operating Cash Flow-207778474644383355425324250212
Capital Expenditures-83.70-184-78.00-38.00-49.80-47.40-31.91-112-35.98-18.64
Free Cash Flow-290594396606333308393212214193
Cash & Equivalents1,4861,4169271,051954696694479403627
Total Debt850250250--126282276266305
Net Cash / Debt6361,1666771,051954569411203138322
Assets3,9133,4012,8792,3262,1841,8842,0881,6271,5181,432
Liabilities1,133593758463585619783532559537
Book Value2,7802,7892,1021,8511,5891,2421,2591,084948884
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name United Therapeutics Corporation
Country United States
Employees 920
CEO Martine A. Rothblatt

Stock Information

Ticker Symbol UTHR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: UTHR
IPO Date June 17, 1999

Description

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.